Quick Answer
Milk Thistle Liver Enzyme Randomized Trial has evidence relevant to safety, limits, and clinician-discussion contexts, but conclusions should stay close to the cited sources. One representative finding is: Introduction Metabolic dysfunction-associated steatotic liver disease (MASLD) lacks treatment options, with few evidence-based choices beyond lifestyle modification.
Key Takeaways
- 01Introduction Metabolic dysfunction-associated steatotic liver disease (MASLD) lacks treatment options, with few evidence-based choices beyond lifestyle modification. [Messier H (2026)]
- 02Discussion This study provides preliminary evidence that this organic nutraceutical may improve steatosis grade in individuals with MASLD. [Messier H (2026)]
- 03This is the first clinical study to assess the efficacy of an organic liquid oral nutraceutical composed of turmeric extract, dandelion powder, milk thistle extract, and ginger powder in MASLD. [Messier H (2026)]
- 04Chronic liver disease is emerging as a public health priority in India, with the incidence of metabolic dysfunction-associated steatotic liver disease ranging between 8 and 20% depending on the region and contributing to 10 to 15% of deaths due to chronic liver disease (). [Patel Ghanashyam (2026)]
The current Migaku evidence database contains 2 reusable source documents for Milk Thistle Liver Enzyme Randomized Trial. This answer focuses on safety, limits, and clinician-discussion contexts.
- Introduction Metabolic dysfunction-associated steatotic liver disease (MASLD) lacks treatment options, with few evidence-based choices beyond lifestyle modification. [Messier H (2026); evidence level 2]
- Discussion This study provides preliminary evidence that this organic nutraceutical may improve steatosis grade in individuals with MASLD. [Messier H (2026); evidence level 2]
- This is the first clinical study to assess the efficacy of an organic liquid oral nutraceutical composed of turmeric extract, dandelion powder, milk thistle extract, and ginger powder in MASLD. [Messier H (2026); evidence level 2]
- Chronic liver disease is emerging as a public health priority in India, with the incidence of metabolic dysfunction-associated steatotic liver disease ranging between 8 and 20% depending on the region and contributing to 10 to 15% of deaths due to chronic liver disease (). [Patel Ghanashyam (2026); evidence level 2]
- Ginger () has been found to support healthy liver function, and to have antioxidant properties (). [Patel Ghanashyam (2026); evidence level 2]
Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording.
This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.
Sources
- Effectiveness and safety of an ayurvedic nutraceutical for improving clinical parameters of liver function in participants with metabolic dysfunction-associated steatotic liver disease: a randomized, placebo-controlled, preliminary phase 2 exploratory clinical trial.
- Long-term safety and efficacy of a highly purified plant-based nutraceutical for improving clinical parameters of liver function in healthy participants: a randomized, double-blind, placebo-controlled clinical trial